Restenosis

New Data Presented at LINC 2019 Demonstrates Acute Success with DABRA Excimer Laser System for the Treatment of Peripheral Artery Disease

Retrieved on: 
Wednesday, February 20, 2019
Surgery, Health, Cardiology, Hospitals, Pharmaceutical, Medical specialties, Medicine, Organ systems, Statistical hypothesis testing, Neurosurgery, Statistical significance, Vascular surgery, Carotid artery stenosis, Restenosis

A statistically significant difference was demonstrated in pre- and post-diameter stenosis (p

Key Points: 
  • A statistically significant difference was demonstrated in pre- and post-diameter stenosis (p
  • DABRA is a safe, versatile and simple catheter and laser system for the treatment of mixed morphology vascular blockages above- and below-the-knee.
  • DABRA, launched in 2017, is used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.
  • Forward-looking statements in this press release include, but are not limited to, statements regarding the potential patient outcomes using the DABRA catheter and laser system.

Europe Angioplasty Balloons Market 2018-2025 - Increase In Number Of Market Players Restraining the Market

Retrieved on: 
Thursday, October 4, 2018
Medicine, Clinical medicine, Interventional radiology, Circulatory system, Angioplasty, Balloon catheter, Percutaneous coronary intervention, Stent, Cutting balloon, Catheter, Balloon, Restenosis

Europe angioplasty balloons market is expected to grow at a healthy CAGR in forecast period.

Key Points: 
  • Europe angioplasty balloons market is expected to grow at a healthy CAGR in forecast period.
  • The Europe angioplasty balloons market is segmented on the basis of type into Plain old balloon angioplasty, Drug-Coated Balloon (DCB) angioplasty, Cutting Balloons, Scoring Balloons and Stent graft balloon catheter.
  • The Europe angioplasty balloons market on the basis of material is segmented into Nylon, Polyurethane, Silicone Urethane Co-Polymers and Other.
  • The Europe angioplasty balloons market on the basis of Disease Indication is segmented into Coronary angioplasty, Venous angioplasty, Carotid angioplasty, Renal artery angioplasty and Peripheral angioplasty.

Coronary Stents Market - Global Forecast to 2026: Technological Advancement in Stent Development to Minimize Restenosis and Improve Patient Compliance

Retrieved on: 
Monday, September 24, 2018
Medicine, Interventional cardiology, Clinical medicine, Medical devices, Drug-eluting stent, Percutaneous coronary intervention, Coronary stent, Restenosis, Stent, Bare-metal stent, Phosphorylcholine

The global coronary stents market was valued at US$ 6,216.7 Mn in 2017, and is expected to reach US$ 11,622.5 Mn by 2026, expanding at a CAGR of 7.3% from 2018 to 2026.

Key Points: 
  • The global coronary stents market was valued at US$ 6,216.7 Mn in 2017, and is expected to reach US$ 11,622.5 Mn by 2026, expanding at a CAGR of 7.3% from 2018 to 2026.
  • In the last 2 decades there has been technological advancement in the manufacturing of stents to counteract complication such as restenosis and stent-in-stent procedure.
  • The only limitation the coronary stents market face is the exorbitant price of drug eluting stents and competition exerted by percutaneous coronary intervention.
  • Drug eluting stents are currently dominating the coronary stents market on account of key factors such as rising prevalence of coronary artery stenosis, technological advancement in the formulation of biodegradable polymers containing antiproliferative agents to prevent restenosis.

Boston Scientific Receives U.S. FDA Approval for the Eluvia™ Drug-Eluting Vascular Stent System

Retrieved on: 
Monday, September 24, 2018
Medicine, Interventional cardiology, Health care, Medical devices, Health, Interventional radiology, Stent, Drug-eluting stent, Boston Scientific, Femoral artery, Peripheral artery disease, Restenosis

MARLBOROUGH, Mass., Sept. 24, 2018 /PRNewswire/ --Today, Boston Scientific (NYSE: BSX) announced that the U.S. Food and Drug Administration (FDA)has approved its Premarket Approval (PMA) application to market the Eluvia Drug-Eluting Vascular Stent System, specifically developed for the treatment of peripheral artery disease (PAD).

Key Points: 
  • MARLBOROUGH, Mass., Sept. 24, 2018 /PRNewswire/ --Today, Boston Scientific (NYSE: BSX) announced that the U.S. Food and Drug Administration (FDA)has approved its Premarket Approval (PMA) application to market the Eluvia Drug-Eluting Vascular Stent System, specifically developed for the treatment of peripheral artery disease (PAD).
  • "With the FDA's approval of the Eluvia stent, we can now bring the transformative power of sustained drug release to clinicians and the millions of patients suffering from this terrible disease."
  • The FDA's approval is based on findings from the IMPERIAL trial, in which the Eluvia stent demonstrated superior results in the first superficial femoral artery head-to-head drug-eluting stent trial.
  • The Eluvia stent system is built on the Innova Stent System platform, a self-expanding nitinol stent that has been designed for use in the superficial femoral and proximal popliteal arteries, the main arteries that supply blood to the legs.